|
|
|||||||||||||||||||||||||||||||||||||||
|
Guardant Health Inc (GH) Guardant Health is a precision oncology company focused on helping conquer cancer through use of its proprietary tests, data sets and analytics. Co.'s Guardant Health Oncology Platform is designed to utilize its capabilities in technology, clinical development, regulatory and reimbursement. Co. engages in the clinical liquid biopsy market with its tests. Co.'s Guardant360 test is a molecular diagnostic test measuring cancer-related genes, and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. Co. has launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to address the need in Stage II-III colorectal cancer.
|
|
|||||||||||||||||||||||||||||||||||||||
Free GH Email Alerts:
Guardant Health Inc (GH) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.